Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

FDA Clearance for clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia (CLL)

This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.

This is good news for CLL patients as measurement for MRD (minimal or measurable residual disease) is increasingly being recognized as an important data point in treatment decisions for some limited duration therapies. This is already true in many clinical trials, but the change will now be more relevant in the clinic.

Here is the official press release.

With a doctor’s order, patients can have the test done at Labcorp or even use the services of a mobile phlebotomist.